NCT06984289Completed
US Radiomics in Advanced Cervical Cancer
Role of Radiomics Applied to Ultrasound in Patients With Locally Advanced Cervical Cancer: a Retrospective Multicenter Study
Source: ClinicalTrials.gov · Last updated 22 May 2025
Brief summary (registry, in English)
This is a retrospective, multicenter observational study aimed at evaluating the role of ultrasound-based radiomics in patients with locally advanced cervical cancer (LACC). The study will analyze pre-treatment ultrasound images to identify radiomic features that may predict treatment response and disease recurrence. A total of 220 patients treated with exclusive chemoradiotherapy or neoadjuvant chemoradiotherapy followed by radical surgery between 2011 and 2024 will be included. Using clinical and imaging data, machine learning models will be developed to distinguish between responders and non-responders, and to identify patients at higher risk of relapse. The goal is to improve personalized care in LACC by integrating radiomic analysis into treatment planning and follow-up strategies.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 220 (actual)
- First submitted
- 14 May 2025
- Start date
- 25 Mar 2025
- Primary completion date
- 30 Apr 2025
- Lead sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Diseases
- Cervical cancer
- NCT number
- NCT06984289
What you commit to
- Study type: Observational
- Participants enrolled: 220
- From 25 Mar 2025 to the primary completion date, 30 Apr 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- Age \<18 years
Other
- Only printed ultrasound images available
- Ultrasound images with poor tumor visualization or with text/markers obscuring the tumor
Who the study is looking for
- Female patients aged ≥18 years
- Histologically confirmed diagnosis of locally advanced cervical cancer (FIGO 2018 stage IB3-IVA, excluding IIA1)
- Histologic subtypes: squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma
- Underwent transvaginal or transrectal ultrasound prior to treatment
- At least one pre-treatment DICOM ultrasound image of the primary tumor available
- Treated with either exclusive chemoradiotherapy or neoadjuvant chemoradiotherapy followed by radical surgery
- Completed at least 12 months of follow-up after primary treatment
- Signed informed consent (or equivalent declaration)
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS Coordinator of this site? Confirm its status | Roma | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.